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rats, which recognize AQP4268–285 as their specific anti-
gen and cause severe panencephalitis. These T cells are re-
activated behind the blood–brain barrier and deeply infil-
trate the CNS parenchyma of the optic nerves, the brain, 
and the spinal cord, while T cells with other AQP4-pep-
tide specificities are essentially confined to the meninges. 
Although AQP4268–285-specific T cells are found throughout 
the entire neuraxis, they have NMO-typical “hotspots” for 
infiltration, i.e. periventricular and periaqueductal regions, 
hypothalamus, medulla, the dorsal horns of spinal cord, and 
the optic nerves. Most remarkably, together with NMO-
IgG, they initiate large astrocyte-destructive lesions which 
are located predominantly in spinal cord gray matter. We 
conclude that the processing of AQP4 by antigen present-
ing cells in Lewis rats produces a highly encephalitogenic 
AQP4 epitope (AQP4268–285), that T cells specific for this 
epitope are found in the immune repertoire of normal 
Lewis rats and can be readily expanded, and that AQP4268–
285-specific T cells produce NMO-like lesions in the pres-
ence of NMO-IgG.
Keywords CNS inflammation · Neuromyelitis optica · T 
cells · Aquaporin 4 · ENMO
Introduction
Neuromyelitis optica (NMO) is an inflammatory, astrocy-
topathic disease of the central nervous system (CNS) [8, 
36]. Ever since the hallmark of this disease—the pres-
ence of pathogenic autoantibodies in the serum of most 
NMO patients [19, 20]—has been recognized, a lot of 
effort has been made to study the role of antibodies and 
T cells in lesion formation and expansion. Based on these 
studies we know (1) that in most patients, the pathogenic 
Abstract In neuromyelitis optica (NMO), astrocytes 
become targets for pathogenic aquaporin 4 (AQP4)-spe-
cific antibodies which gain access to the central nervous 
system (CNS) in the course of inflammatory processes. 
Since these antibodies belong to a T cell-dependent sub-
group of immunoglobulins, and since NMO lesions con-
tain activated CD4+ T cells, the question arose whether 
AQP4-specific T cells might not only provide T cell help 
for antibody production, but also play an important role in 
the induction of NMO lesions. We show here that highly 
pathogenic, AQP4-peptide-specific T cells exist in Lewis 
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autoantibodies are directed against aquaporin 4 (AQP4), 
a water channel enriched on astrocytic endfeet at the 
perivascular and subpial glia limitans [20, 27], (2) that 
these antibodies belong to the IgG1 subgroup of immuno-
globulins which need T cell help in their formation [20], 
and (3) that these antibodies have additional requirements 
for T cells in lesion formation: They need them for open-
ing of the blood–brain barrier to gain access to the CNS 
parenchyma [6, 7, 14], and they need them to create a CNS 
environment facilitating antibody-dependent cellular cyto-
toxicity (ADCC) and complement-mediated cytotoxicity 
(CDC) against their astrocytic targets [15, 33]. Such an 
environment is only created by T cells which are activated 
within the CNS [33], which is in line with the presence 
of Ox40+ CD4+ T cells in early lesions of human NMO 
patients and their experimental counterparts [33]. In order 
to become activated within the CNS, CD4+ T cells must 
encounter “their” specific, CNS-intrinsic antigen in the 
context of MHC class II products [13]. Considering the 
facts that AQP4-specific T cells provide help to the forma-
tion of AQP4-specific antibodies, and that AQP4-specific 
T cells are clonally expanded in NMO patients [23, 38], 
it is tempting to speculate that the antigen leading to T 
cell activation within the CNS of NMO patients is AQP4 
as well. However, T cell responses against AQP4 target 
a surprisingly large number of epitopes in humans [22, 
37] and even in single patients [23], which is reflected in 
Lewis rats [32] and in C57BL/6 or SJL/J mice [12, 25] 
(Fig. 1). Moreover, until recently, only weakly pathogenic 
AQP4 peptide-specific T lymphocytes could be derived 
from Lewis rats [32]. These T cells essentially pile up in 
the meninges, but hardly infiltrate the CNS parenchyma, 
suggestive of a limited activation of these cells [13, 32, 
33]. AQP4-reactive T cells could also be obtained after 
immunization of C57BL/6 aquaporin-4 null mice with a 
combination of the human AQP4 extracellular loop pep-
tides AQP456–69, AQP4135–153, and AQP4212–230 in complete 
Freund’s adjuvans and subsequent in vitro polarization 
of the peptide-specific T cells towards a TH17 phenotype 
[10]. These T cells were encephalitogenic, as evidenced 
by the induction of inflammatory lesions in spinal cords 
and optic nerves and by the induction of clinical signs of 
CNS inflammation, but derived from animals which did 
not have to overcome immunological tolerance, due to 
the absence of AQP4. In addition, the animals have been 
challenged with human instead of murine AQP4 [10]. 
Cumulatively, the findings obtained from both animal 
models raised the questions whether strongly encepha-
litogenic AQP4-specific T cells exist at all in the normal 
immune repertoire, and whether these cells can guide 
Fig. 1  Aquaporin 4 epitopes used for T cell recognition in humans, 
rats and mice. The black bar shown here on the top represents the 
AQP4 isoform M23 and the location of intracellular (I, blue), trans-
membraneous (T, white) and extracellular sequences (E, blue) in this 
molecule assigned according to Verkman et al. [39]. The black, num‑
bered lines underneath show the location and the start/end position of 
the amino acid sequence of AQP4 epitopes described in humans [4, 
23, 38], SJL/J [25] and C57BL/6 [12, 25] mice, C57BL/6 AQP4 null 
mice [10] and in Lewis rats ( [31] and current publication)
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astrocyte-destructive lesions to NMO-typical sites. These 
questions were addressed in the current study, using Lewis 
rats as a model organism.
Materials and methods
Animals
Lewis rats (7–8 weeks old) were obtained from Charles 
River Wiga (Sulzfeld, Germany). They were housed in 
the Decentral Facilities of the Institute for Biomedical 
Research (Medical University Vienna) under standardized 
conditions. The experiments were approved by the Ethic 
Commission of the Medical University Vienna and per-
formed with the license of the Austrian Ministry for Sci-
ence and Research.
Characterization of the immunoglobulins used 
in transfer experiments
The NMO-IgG preparations containing pathogenic AQP4-
specific antibodies derived from therapeutic plasmaphe-
resates/sera of two different patients (“NMO-IgG9” and 
“pt1”; both NMO-IgGs worked equally well). The NMO-
IgGs were essentially prepared and purified as described 
[7], and adjusted to an IgG concentration of 10 mg/
ml. The use of it for research was approved by the Eth-
ics Committee of Tohoku University School of Medicine 
(No. 2007-327) and by the Regional and National Ethical 
Committee of Hungary (3893.316-12464/KK4/2010 and 
42341-2/2013/EKU). The normal human IgG prepara-
tion used as a negative control was commercially available 
(Subcuvia™, Baxter, Vienna), and was also diluted with 
phosphate-buffered saline (PBS) to an IgG concentration of 
10 mg/ml prior to use.
Antigens
For immunization and T cell isolation/propagation, large 
peptides or fusion proteins containing predicted epitopes 
[32] were used (Table 1). These peptides were synthesized 
by Centic Biotec (Heidelberg, Germany), or, in the case of 
the human AQP-4 peptide AQP-4278–323, were expressed 
in E. coli using the pBAD/TOPO ThioFusion Expression 
System (Invitrogen, Carlsbad, CA, USA) and purified as 
described [32].
For specificity tests (see below), also full-length human 
M23 AQP4 (gene bank accession number: NP-004019) 
was used, which has 100 % identity to the rat epitopes con-
tained in AQP4207–232 (PAVIMGNWE) and AQP4268–285 
(QQTKGSYME and TKGSYMEVE), and contains the 
human sequence of AQP4 recognized by AQP4278–323-spe-
cific T cells (GVVHVIDVD and HVIDVRGE, Table 1). 
For the preparation of this protein, HEK293A cells were 
transiently transfected with pcDNA3.1(M23)AQP4, allow-
ing the production of AQP4 as a 6-HIS-tagged protein. 
72 h later, the cells were washed with sterile phosphate-
buffered saline (PBS) and exposed to lysis buffer (10 mM 
Tris buffer pH7.5, 100 mM NaCl, 1 mM EDTA, 1 % Tri-
ton X-100 and complete protease inhibitor cocktail tablet) 
for 1 h at 4 °C. The lysate was thoroughly mixed by pipet-
ting, subjected to repeated rounds of freezing and thaw-
ing, sonicated using a Sonopuls GM70 (Bandelin, Berlin, 
Germany), and finally passaged through a 23 gauge needle. 
Ni NTA-Agarose Superflow (Qiagen) was then used for 
the purification of AQP4 following the instructions of the 
manufacturer. Briefly, Ni NTA beads were gently applied to 
a column, washed with 5 volumes of wash buffer (20 mM 
Tris/125 mM NaCl) prior to applying the lysate mix diluted 
1:1 in wash buffer containing 1 % Triton X-100. Following 
washing steps with 10 volumes of wash buffer containing 
1 % Triton X-100, we were washing the column with 10 
Table 1  Peptide and epitope sequences
Unless otherwise stated, the peptides/epitopes and amino acid sequences derive from the rat AQP4 sequence (GI:5019990)
a This peptide and the corresponding amino acid sequences and epitopes derive from the human AQP4 sequence (GI:4502181)
Peptide Amino acid sequence Epitopes contained
AQP427–69 KGVWTQAFWKAVTAEFLAMLIFVLLSVGSTINWGGSENPLPVD p33–41: AFWKAVTAE
p55–63: STINWGGSE
AQP4171–190 VFTIFASCDSKRTDVTGSVA p176–184: ASCDSKRTD
AQP4207–232 YTGASMNPARSFGPAVIMGNWENHWI p220–228: PAVIMGNWE
AQP4237–277 PIIGAVLAGALYEYVFCPDVELKRRLKEAFSKAAQQTKGSY p241–249: AVLAGALYE
p249–257: EYVFCPDVE
AQP4268–285 KAAQQTKGSYMEVEDNRS p271–279: QQTKGSYME
p273–281: TKGSYMEVE
AQP4a278–323 MEVEDNRSQVETDDLILKPGVVHVIDVDRGEEKKGKDQSGEVLSSV p297–305: GVVHVIDVD
p300–308: HVIDVDRGE
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volumes of washing buffer containing 0.1 % Triton X-100. 
Subsequently, we eluted AQP4 in 20 mM Tris/125 mM 
NaCl/0.1 % Triton X-100/600 mM Imidiazole. Follow-
ing dialyses against PBS we used AQP4 in a concentration 
of 1 mg/ml in PBS/0.1 % Triton X-100. The eluted AQP4 
protein was confirmed by Western blot (data not shown). 
In specificity tests, also recombinant human MOG1–125 
was used, which was essentially produced and purified as 
described [3]. The MOG35–55-specific T cells used were 
raised against rat/mouse MOG35–55 (Sigma).
Immunization and T cell line preparation
The animals were subcutaneously immunized with 100 µl of a 
1:1 mixture of the relevant antigen (stock 2 mg/ml) in Freund’s 
incomplete adjuvans supplemented with 4 mg/ml mycobacte-
rium tuberculosis H37Ra. 9–11 days after the immunization, 
the animals were killed. At this point, they were all clinically 
healthy and did not show any evidence for inflammation of the 
CNS or of peripheral organs. The lymph nodes draining the 
immunization site were removed, and peptide-specific T cell 
lines were established as described [32, 33].
Isolation of naïve T cells
The naïve T cells tested derived from the spleen of an adult 
Lewis rat housed under specific pathogen-free conditions. 
The spleen was processed to a single cell suspension, and 
contaminating erythrocytes were removed by incubation 
of the cells for 5 min in hypotonic salt solution (0.15 M 
NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA) pH 7.4.
Preparation of T cells for immunocytochemistry
T cells were embedded in HistoGel (Thermoscientific, 
Cheshire, UK) according to the manufacturer’s instructions 
and subsequently fixed with 4 % paraformaldehyde for 
24 h. The HistoGel blocks were then processed for immu-
nohistochemical analysis as detailed [2, 7].
Characterization of T cell lines
Specificity tests
Specificity was determined in T cell proliferation assays, 
using 96 well plates. 5 × 105 AQP4-peptide-specific T cells 
were cocultured in triplicates with 1 × 106 thymic antigen 
presenting cells in the absence of externally added antigen 
or in the presence of irrelevant CNS antigens (i.e. myelin 
basic protein or unrelated AQP4-peptides; 10 µg/ml final) as 
negative controls, of the peptide against which the cell line 
was established as specific antigen (10 µg/ml final), or of 
concanavalin A (2.5 µg/ml final) as positive control [9, 11].
The human M23 AQP4 preparation had a protein con-
centration of 1 mg/ml in phoshate-buffered saline/0.1 % 
Triton X-100. To avoid the toxic effects of Triton X-100, 
we diluted the antigen preparation 1:100 with PBS and 
coated it in 100 µl aliquots over night at 4 °C onto flat-bot-
tom 96-well plates. On the next morning, the coating solu-
tion was drained from the plates, and each well was washed 
gently and briefly with 100 µl culture medium containing 
1 % rat serum. Then, 1 × 106 thymic antigen presenting 
cells in 100 µl medium were cultured in these plates for 8 h 
at 37 °C prior to the addition of T cells. Exactly the same 
procedure was applied to recombinant human MOG1–125.
The cells were cultured for 48–72 h. For the final 
18–24 h in culture, [3H]-thymidine was added to reveal de 
novo DNA synthesis during the S-phase of the cell cycle of 
activated T cells.
Analysis of surface marker expression by flow cytometry
For staining, the cells were incubated for 30 min at room 
temperature with antibodies against rat CD4 (W3/25, 
mouse monoclonal, Serotec) or mouse IgG1 (Dako, 
Glostrup, Denmark; isotype matched control antibody). 
After washing, the cells were incubated for 30 min at 
room temperature for 30 min with polyclonal Alexa488-
labeled goat anti-mouse IgG (Jackson ImmunoRe-
search). For staining of the αβ-T cell receptor (TCR), 
PE-labeled mouse anti-αβTCR (eBioscience, San Diego, 
CA) was used. All antibodies were used in a dilution of 
1:100 in stain buffer (PBS/10 % fetal calf serum/1 mM 
EDTA).
Quantitative real‑time polymerase chain reaction (qPCR) 
for the detection of transcripts for IFN‑γ and IL‑17
RNA was purified from freshly activated T cell blasts using 
the RNeasy Plus Mini Kit (Qiagen GMbH, Hilden, Germany). 
Genomic DNA was removed and the RNA transcribed to cDNA 
as described [16]. qPCR was performed using the SsoAdvanced 
Universal SYBR Green Supermix (Bio-Rad) according to the 
manufacturer’s instructions, using a 10 µl reaction mixture [5 µl 
SsoAdvanced Universal SYBR Green Supermix, 0.2 µl forward 
primer (10 pmol/µl), 0.2 µl reverse primer (10 pmol/µl), 3.6 µl 
double-distilled H2O, 1 µl DNA template] in a StepOnePlus 
system (applied biosystems). The following primers were used: 
IL-17 forward: 5′-TACCAGCTGATCAGGACGAG-3′; IL-17 
reverse: 5′-CATCAGGCACATGGATGGAA-3′; IFN-γ forward: 
5′-ATTCATGAGCATCGCCAAGTTC-3′; IFN-γ reverse: 
5′-TGACAGCTGGTGAATCACTCTGAT-3′; GAPDH for-
ward: 5′-CCGAGGGCCCACTAAAGG-3′; GAPDH reverse: 
5′-ATGGGAGTTGCTGTTGAAGTCA-3′. For qPCR, an ini-
tial denaturation step (95 °C, 30 s) was followed by 40 cycles 
of denaturation (95 °C, 15 s) and annealing/extension (60 °C, 
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1 min). The absence of unspecific amplification was determined 
by melt curve analysis. All reactions were run in triplicates.
Induction of experimental autoimmune 
encephalomyelitis (EAE) and experimental 
autoimmune neuromyelitis optica (ENMO)
EAE was induced in Lewis rats by intraperitoneal trans-
fer of activated AQP4-peptide-specific T cells. The num-
bers of T cells transferred for each T cell line is shown 
in Fig. 2. The animals were monitored daily for weight 
loss and clinical signs of EAE, which was scored accord-
ing to the following scheme: 0: healthy; 0.5: partial loss 
of tail tonus; 1: complete loss of tail tonus; 2: hind limb 
weakness, unsteady gait; 3: hind limb paralysis (this was 
for ethical reasons set as endpoint for EAE experiments). 
The animals were killed by an overdose of CO2 on days 
5/6 after T cell-transfer, and perfused with 4 % phosphate-
buffered paraformaldehyde (PFA). Brains and spinal cords 
were dissected, immersed for another 18–24 h in PFA and 
embedded in paraffin for histological analysis. For the 
induction of ENMO, AQP4-peptide-specific T cells were 
injected intraperitoneally on day 0, followed by an intra-
peritoneal injection with 1 ml phosphate-buffered saline 
(PBS) containing either 10 mg NMO-IgG or 10 mg nor-
mal human IgG on day 5. Also these animals were killed 
on day 7 after T cell-transfer with CO2, and perfused with 
4 % PFA.
Fig. 2  Inflammatory brain 
lesions after injection of aqua-
porin 4 peptide-specific T cells. 
Brain sections with lesions 
induced by AQP4171–190 (a), 
AQP427–69 (b), AQP4278–323 (c), 
AQP4237–277 (d), AQP4207–232 
(e), and AQP4268–285-specific 
T cells (f) were stained with 
anti-CD3 antibodies to reveal 
T cells (brown) and hema-
toxylin to show nuclei (blue). 
Bars 100 µm. Also shown are 
the average numbers of T cells 
which had to be injected in 
order to reliably get lesions, 
the average number of lesions 
per animal and the number of 
animals injected
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Antigen injections into the cisterna magna
On day 5 after EAE induction by T cell transfer, the ani-
mals were anesthetized with Ketanest S/Rompun. After-
wards, the neck of the animals was flexed, and the skin was 
cut open to expose the atlanto-occipital membrane, which 
was then punctured with a thin glass capillary. When the 
entry of clear cerebrospinal fluid into the capillary indi-
cated the accuracy of the injection site, 5 µl of AQP4 pep-
tides (dissolved in a concentration of 2 mg/ml in RPMI), or 
of RPMI alone were injected slowly. Afterwards, the capil-
lary was withdrawn and the skin was closed with wound 
clips. 24 h later, the animals were killed with CO2 and 
perfused with 4 % PFA. Brains and spinal cords were pro-
cessed for immunohistochemical analysis as detailed [2, 7].
Immunohistochemistry
All stainings were done essentially as described [2, 7] using 
the mouse monoclonal antibody ED1 (to stain macrophages 
and activated microglia; Serotec, Germany), rabbit poly-
clonal antibodies against CD3 (to stain T cells; NeoMarkers, 
Fremont, USA), rabbit polyclonal antibodies against AQP4 
(to stain astrocytes; Sigma, Germany), rabbit polyclonal or 
mouse monoclonal antibodies against glial fibrillary acidic 
protein (GFAP; from Dako, Denmark, or NeoMarkers, 
respectively), anti-human immunoglobulin (biotinylated 
donkey; polyclonal; Amersham, UK), anti-rat immunoglob-
ulin (biotinylated donkey; polyclonal; Jackson ImmunoRe-
search), and anti-complement C9 (rabbit polyclonal [29]).
For double immunostainings of proliferating cell nuclear 
antigen (PCNA, mouse, clone PC10, DAKO) and CD3 
(rabbit polyclonal; NeoMarkers, Fremont, USA), sections 
were steamed in citrate buffer for 30 min. After incubation 
with mouse anti-proliferating cell nuclear antigen (PCNA, 
clone PC10, DAKO, 1:10 000) over night at 4 °C, the sec-
tions were incubated with alkaline-phosphatase-labeled 
anti-mouse antibodies (Jackson ImmunoResearch, West 
Grove PA, USA, 1:200) for 1 h at RT and developed with 
Fast Blue (FB, Sigma, Germany) substrate. Then the sec-
tions were incubated with rabbit anti-CD3 (polyclonal; 
NeoMarkers, Fremont, USA, 1:2000) over night at 4 °C. 
After incubation with biotinylated anti-rabbit antibodies 
(1:2000) for 1 h at RT and enhancement with CSA (1:1000) 
for 20 min, avidin-peroxidase (Sigma) was applied and the 
sections were developed with aminoethyl carbazole (AEC, 
Sigma).
Quantitative evaluation of immunostained sections
Quantification was done by using a morphometric grid. To 
determine the extent of T cell infiltration, the number of 
CD3+ cells was determined in 3 different areas: within in 
the meninges, within the superficial parenchyma (<100 µm 
distance from the meninges) and within the deep paren-
chyma (>100 µm distance from the meninges).
Statistical evaluation
Statistics were calculated with the IBM SPSS Statistics 
21. The Mann–Whitney (Wilcoxon) W test (comparison of 
medians) was used in all cases. For multiple comparisons, 
Bonferroni correction was used.
Results
All AQP4 epitopes suitable for binding to Lewis rat 
MHC class II (RT1.BL) give rise to antigen‑specific T 
cell responses
We used peptides spanning AQP4 epitopes previously identi-
fied as potential binders to RT1.BL of Lewis rats [32] for the 
immunization of Lewis rats. Although all animals remained 
clinically healthy upon immunization, they mounted T cell 
responses against all of the peptides used. Consequently, dif-
ferent peptide-specific T cell lines could be established by 
alternating cycles of antigen-specific T cell activation and 
IL-2-driven T cell propagation (Table 1) which constrains 
the generation of TH17 cells [18]. These cells were CD4
+, 
and expressed the αβ T cell receptor (suppl. fig  1). All of 
these cell lines showed a dominant expression of IFN-γ over 
IL-17 (suppl. fig 2), and therefore belonged to the TH1 subset 
of cells. They were all responsive to their specific peptides, 
but the AQP427–69- and AQP4278–232-specific T cell lines did 
not reach a stimulation index >2 (suppl fig. 3).
We tested the encephalitogenic potential of these cells, 
i.e. their ability to induce CNS inflammation, by their 
transfer into naïve Lewis rats.
AQP4‑peptide‑specific T cell lines vary 
in encephalitogenicity and ability for parenchymal 
infiltration
The different AQP4-peptide-specific CD4+ T cells varied 
in their ability to induce CNS inflammation and could be 
grouped into weak, medium, and strongly encephalitogenic 
lines. Weak encephalitogenicity was observed upon trans-
fer of T cells with specificity for AQP4171–190, AQP427–69, 
AQP4278–323, and AQP4237–277. Even after transfer of as 
many as 10 × 107 T cells/animal, these lines were just able 
to yield an average of less than 2 lesions per rat. These 
lesions were essentially located within the meninges, and 
only very few T cells entered the CNS parenchyma (Fig. 2). 
The recipient animals did not show any symptoms of clini-
cal disease, in line with this weak histological evidence 
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of CNS inflammation. Medium encephalitogenicity was 
observed with T cells specific for AQP4207–232 containing 
the epitope PAVIMGNWE. On average, transfer of these 
cells lead to ~10 lesions per animal, distributed along the 
entire neuraxis. However, these cells only barely infiltrated 
the CNS parenchyma. Instead, they piled up in the menin-
ges, resulting in up to 10 layers of T cells on top of each 
other (Fig. 2). Although there was more histological evi-
dence of CNS inflammation than seen with the AQP4 pep-
tide-specific T cells described above, we still did not see 
signs of clinical disease. Strong encephalitogenicity was 
observed in T cells specific for AQP4268–285.
AQP4268–285‑specific T cells are highly encephalitogenic
While for all other cell lines, 3.5-10 × 107 T cells had to be 
transferred to produce inflammatory CNS lesions, as few as 
0.03 × 107 AQP4268–285-specific T cells/animals sufficed to 
do so. For all analysis described below, 3 × 106 AQP4268–
285-specific T cells/animals were used. These cells caused 
CNS inflammation along the entire neuraxis, i.e. in all lev-
els of the spinal cord, throughout the optic nerve, and in 
the entire brain (Figs. 3, 4). “Hotspots” for inflammatory 
lesions were areas around the 3rd and 4th ventricle, in the 
hippocampus, in the periaqueductal gray, in cerebellum and 
medulla, and in the spinal cord in dorsal horns and central 
gray matter (Figs. 3, 4). Lesions at similar sites in the brain 
were also seen after transfer of T cells with other CNS anti-
gen specificities like S100β or MBP (suppl fig. 4). How-
ever, the massive dominance of T cell infiltrates in spinal 
cord gray matter seen with AQP4268–285-specific T cells was 
unique for these cells (suppl. fig 4). The CNS lesions pro-
voked by AQP4268–285-specific T cells were essentially T 
cell-dominated with little microglia activation/macrophage 
recruitment (Figs. 3, 4), and caused weight loss with partial 
loss of tail tonus as sole clinical symptom. Some AQP4268–
285-specific T cells were found in the meninges, but a much 
larger proportion of these cells was able to infiltrate the 
CNS gray and white matter parenchyma than seen with any 
other AQP4-peptide-specific T cell line before (Figs. 3, 4).
AQP4207–232‑ and AQP4268–285‑specific T cells differ 
in their extent of activation within the CNS
Why are AQP4268–285-specific T cells able to deeply immi-
grate into the CNS parenchyma, while all other AQP4peptide-
specific T cells studied so far pile up in the meninges? To 
address this question, we made T cell proliferation assays 
to analyze whether antigen presenting cells can process 
full-length AQP4 to produce and present T cell epitopes 
to AQP4207–232-, and AQP4268–285-specific T cells. We 
Fig. 3  Inflammation of spinal cord and optic nerve provoked by 
AQP4268–285-specific T cells. Shown here are cross sections of tho-
racic spinal cord (a, b), longitudinal sections of the optic nerve (c, d) 
and a coronal section of the brain at the level of the optic chiasm (e), 
reacted with antibodies against CD3 to reveal T cells (a, c, e, brown) 
and with the antibody ED1 to show activated microglia/macrophages 
(b, d, brown). Counterstaining was done with hematoxylin to reveal 
nuclei (blue). Bars 1 mm
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observed that these T cells became activated and prolifer-
ated in the presence of AQP4 and syngenic antigen present-
ing cells (Fig. 5; suppl fig. 5), indicating that the epitopes 
recognized arise from naturally processed AQP4. We next 
focused on AQP4268–285-specific T cells and on AQP4207–
232-specific T cells as “prototype” for all other AQP4peptide-
specific T cells and studied the activation of AQP4268–285- 
and AQP4207–232-specific T cells in the CNS. It was not 
Fig. 4  Inflammation of the 
brain provoked by AQP4268–
285-specific T cells. Shown here 
are coronal sections of the brain 
at the level of the 3rd ventricle/
hippocampus (a, b), the 4th 
ventricle/medulla (c), midbrain/
periaqueductal gray (d), and 
basal hypothalamus/eminentia 
mediana (e) reacted with anti-
bodies against CD3 to reveal T 
cells (a, c, d, e, brown) and with 
the antibody ED1 to show acti-
vated microglia/macrophages 
(b, brown). Counterstaining was 
done with hematoxylin to reveal 
nuclei (blue). The inflammatory 
sites shown are representa-
tive for 5 animals analyzed. 
Bars 1 mm
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possible to re-isolate and characterize these cells by FACS 
analysis, since AQP4207–232-specific T cells had to be used 
in extremely high cell numbers for EAE induction (Fig. 2) 
and caused only few lesions of small size. Instead, we 
studied T cell activation by immunohistochemistry, using 
double stainings with CD3 as T cell marker, and with the 
proliferating cell nuclear antigen PCNA as activation 
marker. To ensure that PCNA is a reliable marker for T cell 
activation, we first tested the anti-PCNA antibody in vitro, 
using T cells cultured for different lengths of time after their 
antigen-specific activation. We observed, that PCNA was 
detectable in 90 % of the T cells on day 0 after a 48 h-last-
ing T cell activation by antigen in the context of RT1.BL, in 
80 % of the T cells on day 2, in 50 % of T cells on day 4, 
and became essentially undetectable (<1 %) in T cells on 
day 6 (Fig. 6). We next evaluated the percentage of activated 
PCNA+ AQP4268–285- specific T cells in the total CD3
+ T 
cell pool, depending on the depth of parenchymal infiltra-
tion. In medians, 14 % PCNA+ CD3+ T cells were found 
in the meninges, 32 % located in the superficial, and 44 % 
in the deep parenchyma. Cumulatively, these data showed 
that AQP4268–285-specific T cells are much better activated 
in the CNS than AQP4207–232-specific T cells. What restricts 
the activation of AQP4207–232-specific T cells?
The amount of available AQP4207–232‑peptide limits 
CNS infiltration by AQP4207–232‑peptide‑specific T cells
To test whether low amounts of AQP4207–232 preclude effi-
cient T cell activation and subsequent parenchyma infiltra-
tion, we increased its concentration by injecting AQP4207–232 
into the cisterna magna at the very onset of AQP4207–232-pep-
tide-specific T cell-mediated EAE [1, 42]. Intracisternal 
injections of an irrelevant AQP4 peptide (AQP4236–277) 
and of vehicle (=RPMI) into AQP4207–232-peptide-specific 
T cell-challenged rats, and of peptides AQP4236–277 and 
AQP4207–232 into naïve rats served as controls. The animals 
were killed 24 h later for immunohistochemical analyses. 
When AQP4207–232 was injected into the cisterna magna, 
33 % of the T cells migrated into the deep parenchyma, 
while this was the case for only 7.5 % of the T cells when 
the irrelevant AQP4236–277 peptide has been used (data not 
shown). Moreover, 25 % of the CD3+ T cells found in the 
deep parenchyma had an activated phenotype, as evidenced 
by the expression of PCNA (Fig. 7). The most likely source 
of these activated T cells are the AQP4207–232-specific T cells 
which had been injected into these animals to induce EAE, 
since we did not see PCNA expression in naïve T cells cul-
tured without any antigen, or cultured in the presence of 
AQP4207–232 and splenic antigen presenting cells (Fig. 7).
Hence, T cell activation and subsequent parenchymal 
infiltration by AQP4207–232-peptide-specific T cells can be 
increased by injections of AQP4207–232 into the cisterna magna.
In the presence of NMO‑IgG, the numbers 
of pathogenic T cells determine location and size 
of astrocyte‑destructive lesions
We have shown above that AQP4268–285-specific T cells are 
sufficiently activated to immigrate the CNS parenchyma. 
Are they also sufficiently activated to allow the formation 
Fig. 5  AQP4 is naturally processed to peptides recognized by 
AQP4207–232- and AQP4268–285-specific T cells. 5 × 105 AQP4-
peptide-specific T cells were cocultured in triplicates with 1 × 106 
thymic antigen presenting cells in the absence of externally added 
antigen or in the presence of irrelevant CNS antigens (i.e. AQP4268–
285 for AQP4207–232-specific T cells or AQP4237–277 for AQP4268–
285-specific T cells; 10 µg/ml final) as negative controls, of the peptide 
against which the cell line was established as specific antigen (10 µg/
ml final), full-length human M23 AQP4 (well coated with 10 µg 
protein) or of concanavalin A (2.5 µg/ml final) as positive control. 
MOG35–55-specific T cells were used as negative control to exclude 
any unspecific effects of the M23 AQP4 coating. T cell activation 
was evidenced by the incorporation of 3H-thymidine and measured 
in counts per minute (cpm). Shown here are the stimulation indices 
(cpm of peptide or protein-exposed cells over cpm of cells cultured 
in the presence of the irrelevant CNS antigen) ±standard deviation. 
Data are representative of several independently performed tests
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of astrocyte-destructive lesions in the presence of NMO-
IgG? To address this question, we challenged Lewis rats 
with AQP4268–285-specific T cells and NMO-IgG, and stud-
ied their spinal cords, optic nerves, and brains by immuno-
histochemistry. When 3 × 106 AQP4268–285-specific T cells 
were used in combination with 10 mg NMO-IgG, the ani-
mals showed loss of tail tonus (EAE score 1) at the day of 
sacrifice (suppl. fig 6), and lesions exhibiting loss of both 
AQP4 and GFAP reactivity almost exclusively confined to 
the spinal cords (54/55 lesions). These lesions were most 
frequently found in thoracic cord gray matter (51.8 %) 
than in cervical (22.2 %) or lumbar/sacral cord gray mat-
ter (18.5 %) (Fig. 8), reaching sizes up to 47,105 µm2. 
Astrocyte-destructive lesions were not seen in the optic 
nerves, and were only detected once in the dorsal medulla 
(1/55 lesions) (Fig. 8, suppl. fig 8). The outcome was differ-
ent, when 2 × 107 AQP4268–285-specific T cells were used 
together with 10 mg NMO-IgG. Then, lesions with AQP4 
loss were not only seen in the spinal cord, reaching sizes 
up to 26,274 µm2, but also in the brain (Fig. 9). The optic 
nerves contained T cell infiltrates and activated microglia/
macrophages, but did not show any evidence of AQP4 loss 
(suppl. fig 8). Lesions with AQP4 loss were also absent 
from optic nerves of 3-week-old rats injected with AQP4268–
285-specific T cells and NMO-IgG (data not shown).
Hence, in the presence of NMO-IgG, low numbers of 
AQP4268–285-specific T cells initiate astrocyte-destructive 
lesions almost exclusively in spinal cord gray matter, while 
higher numbers of AQP4268–285-specific T cells trigger 
additional lesions with AQP4 and GFAP loss in the brain.
Fig. 6  Activation of AQP4 peptide-specific T cells in vitro and 
in vivo. To show that the expression of the proliferating cell nuclear 
antigen (PCNA) depends on T cell activation, AQP4207–232-specific 
T cells were activated with “their” specific peptide in the context of 
RT1.BL, were then purified by density gradient centrifugation and 
cultured in IL-2 containing medium. Immediately after density gra-
dient centrifugation (day 0, a), and after additional 2 (b), 4 (c) and 
6 (d) days in culture, the cells were stained with antibodies against 
the proliferating cell nuclear antigen (PCNA, brown) and counter-
stained with hematoxylin (nuclei blue). e Lesion in the basal hypo-
thalamus induced by AQP4268–285-specific T cells, stained with 
PCNA (blue) and CD3 (red). The arrows point to double-positive 
T cells which immigrated the CNS parenchyma. Please note that 
there is also PCNA staining of activated microglia/macrophages. f 
The percentage of CD3+PCNA+ cells in the CD3+ T cell pool was 
determined within the meninges proper, within the superficial paren-
chyma (<100 µm distance from the meninges) and within the deep 
parenchyma (>100 µm distance from the meninges), using a morpho-
metric grid and ×25 magnification. We counted the cells in 3 differ-
ent lesions/rat brain from 7 different rats after EAE induction with 
AQP4268–285-specific T cells. The differences between the lesion areas 
were significant (Mann–Whitney exact U test and Bonferroni–Holm 
correction; p = 0.0015 (**) for meningeal/superficial-parenchymal 
cells, p = 0.00015 (***) for meningeal/deep parenchymal cells). 
Scale bars 25 µm
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Discussion
Since the discoveries of T cells in NMO lesions [21], and of 
NMO-IgG containing pathogenic AQP4-specific antibodies 
with the T cell-dependent immunoglobulin subclass IgG1 
[19, 20], the question arose whether AQP4 specific T cells 
are only responsible for T cell help in antibody formation, 
or whether they can also participate in directing lesions to 
NMO-typical sites, and induce there astrocyte-destructive 
lesions in the presence of NMO-IgG. And indeed, all AQP4-
specific T cells established so far from wildtype animals 
were only weakly encephalitogenic, targeted the wrong 
sites, and were essentially confined to the meninges, but 
only poorly infiltrated the CNS parenchyma [32]. To finally 
answer these questions, we used one model organism—
Lewis rats—to raise T cell lines against all AQP4 epitopes 
predicted to bind to the MHC class II products (RT1.BL) of 
these animals [40], and to test the encephalitogenic poten-
tial of these cells in vivo. While all of these peptides could 
serve as antigens to produce stable CD4+ TH1 cell lines and 
were fully able to activate T cells in vitro, the vast major-
ity of the resulting AQP4 peptide-specific T cells were only 
weakly or moderately encephalitogenic. Such cells had to 
be transferred in very high numbers into naïve animals, did 
not yield any clinical symptoms, and barely infiltrated the 
CNS parenchyma. However, one of the peptides used, i.e. 
AQP4268–285, was clearly different. It contains two overlap-
ping epitopes (AQP4271–279 with the amino acid sequence 
QQTKGSYME, and AQP4273–281 with the amino acid 
sequence TKGSYMEVE), is the autoantigen of highly 
encephalitogenic T cell responses in Lewis rats, and gives 
rise to T cells which induce clinical symptoms, deeply 
immigrate the CNS parenchyma, and initiate large astro-
cyte-destructive lesions in the presence of NMO-IgG.
What did we learn from these AQP4268–285-specific T 
cells, and how close do we come to an animal model for 
NMO when we use them to induce CNS inflammation in 
combination with pathogenic NMO-IgG in Lewis rats?
Fig. 7  Immigration and activation of AQP4207–232–specific T cells 
into the CNS parenchyma upon intracisternal antigen injection. Tis-
sue sections of Lewis rats which had been injected with AQP4207–
232–specific T cells to induce EAE. On day 5 after T cell transfer, 
the animals received an injection into the cisterna magna of either 
AQP4207–232 as specific antigen (a), AQP4237–277 as irrelevant control 
peptide (b), and vehicle (c), and were sacrificed 24 h later for histo-
logical analysis. Shown here are dorsal medullas, stained with anti-
CD3 antibodies to identify T cells (brown), and with anti-PCNA anti-
bodies to reveal activation of cells (blue nuclei). Scale bars 100 µm. 
d Quantification of the percentage of PCNA+ cells among CD3+ T 
cells in the dorsal medullas, using a morphometric grid for counting 
and a ×10 magnification. Shown here is the percentage of PCNA+ T 
cells (>100 µm distance from the meninges) in the total CD3+ T cell 
pool at this site after EAE induction with AQP4207–232–specific T cells 
and intracisternal injection of either AQP4237–277 (n = 4), AQP4207–232 
(n = 5), or vehicle (n = 6), or in naïve Lewis rats after intracisternal 
injection of AQP4237–277 or AQP4207–232. The differences between the 
treatments with the unspecific (AQP4237–277; n = 4) and the specific 
(AQP4207–232; n = 5) peptide were significant (Mann–Whitney exact 
U test; p = 0,016). Naïve T cells (e) or naïve T cells cultured in the 
presence of AQP4207–232 and spleen-derived antigen presenting cells 
(f) do not express PCNA [anti-CD3 antibodies (red) and anti-PCNA 
antibodies (blue) were used]
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1. AQP4268–285-specific CD4
+ T cells are found in the 
normal healthy immune repertoire, can be read-
ily activated upon immunization, and induce severe 
panencephalitis upon injection into naïve rats. Hence, 
AQP4268–285 is a true self-antigen in Lewis rats.
2. AQP4268–285-specific T cells can immigrate into the 
CNS parenchyma throughout the entire neuraxis, but 
are particularly frequent at sites described to be typical 
for NMO [31]: AQP4268–285-specific T cells cause mye-
litis with a strong involvement of the dorsal horns and 
central gray matter, optic neuritis, and encephalitis with 
profound infiltration around the 3rd and 4th ventricle 
and in the hippocampus, in the periaqueductal gray, in 
the cerebellum and in the medulla. These sites are also 
lesion sites in NMO patients with brain involvement 
[30, 43], which has initially been ascribed to the high 
AQP4 expression at these sites [31]. However, since we 
also see inflammation at these sites, when animals have 
been challenged with other CNS-antigen-specific T 
cells, this distribution of brain lesions is more likely to 
reflect the local action of other regulatory mechanisms 
for T cells and antibody-mediated processes.
3. AQP4268–285-specific T cells yield inflammatory lesions 
in which ~44 % of the deeply infiltrating T cells 
express PCNA as a sign of recent activation. Again, 
this is a crucial point, since T cell activation within the 
CNS is an important prerequisite for the formation of 
astrocyte-destructive lesions in the presence of NMO-
Fig. 8  In the presence of 
NMO-IgG, low numbers of 
AQP4268–285-specific T cells 
initiate astrocyte-destructive 
lesions almost exclusively in 
the spinal cord. a Distribu-
tion of lesions with AQP4 
loss along the neuraxis, using 
schemes provided by Paxinos 
and Watson [28] as guide lines. 
Shown here are brain and spinal 
cord [cervical (C1–7), thoracal 
(T1–10) and lumbar/sacral (L1–
S4)] sections of 3/5 animals, 
and the location of each lesion 
with AQP4 loss was projected 
in red color into the relevant 
scheme. Histological sections 
of the medulla (b), cervical (c) 
and thoracal (d) spinal cord sec-
tions are shown. These sections 
were reacted with anti-AQP4 
antibodies to show the presence 
(brown) and the loss (white) of 
this protein. Counterstaining 
was done with hematoxylin to 
reveal nuclei (blue). Bars 1 mm 
(b) and 0.5 mm (c, d). One 
lesion is shown in consecutive 
sections reacted with ED1 to 
show the presence of activated 
microglia/macrophages (e, 
brown), with antibodies against 
C9 to show the rosette-like 
perivascular complement 
deposition typical for NMO 
lesions (f, red), against AQP4 
(g, brown) and against GFAP 
(h, brown). The sections were 
counterstained with hematoxy-
lin for blue nuclear staining, and 
the bars 125 µm
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IgG lesions [33], and since activated CD4+ T cells are 
found in NMO lesions [33]. It is tempting to speculate 
that this high level of PCNA expression might be due 
to reactivation within the CNS and not due to activa-
tion in vitro before transfer. A supportive, but certainly 
not definitive evidence for this speculation is the low 
number of proliferating AQP4207–232-specific T cells in 
the CNS, which is massively increased by additional 
injection of the respective peptide into the CSF. Unfor-
tunately, however, we cannot formally prove whether 
or not antigen presenting cells in the CNS process anti-
gens in a similar way as their counterparts in vitro do, 
and whether full-length AQP4 is cleaved by these cells 
to AQP4207–232 as efficiently in the CNS as it is in vitro.
4. High numbers of AQP4268–285-specific T cells target 
astrocyte-destructive lesions throughout the entire 
spinal cord, and also to the brain in NMO-IgG sero-
positive hosts. However, when present in low numbers, 
AQP4268–285-specific T cells target 98 % of all astro-
cyte-destructive lesions to cervical/thoracic spinal cord 
gray matter in NMO-IgG seropositive hosts. The pref-
erence of spinal cord is important, since NMO often 
presents with episodes of myelitis. Targeting of this site 
could result from higher levels of expression of AQP4 
mRNA, protein, and large supramolecular aggregates 
in spinal cord and optic nerve relative to other regions 
of the brain [22], and in gray relative to white mat-
ter cord [7]. Higher antigen concentrations might 
then translate to better binding of NMO-IgG, to an 
enhanced availability of this antigen for local antigen 
presenting cells and subsequent T cell activation [24], 
and to an increased astrocytotoxicity of microglia/mac-
rophages via complement- and antibody-mediated cel-
lular mechanisms [33, 34].
 In combination with NMO-IgG, AQP4268–285-specific 
T cells also show a predilection for cervical/thoracic 
spinal cord, which are sites most often affected in 
NMO patients. Since this area is also most frequently 
targeted in the spinal cords of Lewis (LEW), LEW.1 N 
and LEW.1A rats with EAE provoked by the action of 
myelin oligodendrocyte glycoprotein (MOG)-specific 
antibodies and T cells [41], this might point to a gate-
way for autoreactive TH1 cells and antibodies to cross 
the blood–brain barrier at this site, possibly defined by 
regional neural activation [5].
 We do not know yet why in our current NMO model 
the optic nerves are spared from astrocyte-destructive 
lesions, although they contain numerous inflammatory 
Fig. 9  In the presence of 
NMO-IgG, high numbers of 
AQP4268–285-specific T cells 
initiate astrocyte-destructive 
lesions in spinal cord and brain. 
a Distribution of lesions with 
AQP4 loss throughout the brain, 
using schemes provided by Pax-
inos and Watson [28] as guide 
lines. Shown here are coronal 
sections of 2 rats, and the loca-
tion of lesions with AQP4 loss 
was projected in red color into 
the relevant scheme. Coronal 
section cut at midbrain level 
(b) and longitudinal section of 
the spinal cord (c) were reacted 
with anti-AQP4 antibodies to 
show the presence (brown) and 
the loss (white) of this protein. 
Counterstaining was done with 
hematoxylin to reveal nuclei 
(blue). Bars 1.5 mm
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T cells and activated microglia/macrophages. Most 
trivially, the formation of NMO-like lesions in the 
optic nerve could just simply be a rare event in ENMO 
provoked by AQP4268–285-specific T cells and NMO-
IgG, and could become visible when higher numbers 
of animals are examined. Alternatively, also the genetic 
background of our animals might play a role, since 
there is, again, a striking resemblance to the MOG-
induced EAE model described above. In the MOG-
model, demyelinating spinal cord lesions formed in 
LEW.1 N, LEW.1A, LEW.1AV1, BN, and DA rats, but 
additionally in the optic nerves only in BN and DA rats 
[35]. This contribution of genetic background to dis-
ease phenotype could find its human correlate in the 
different, ethnicity-dependent frequencies of longitudi-
nally extensive transverse myelitis seen at onset attack 
in 53 % of Caucasian vs. 33 % of Afro-Caribbean 
patients in an UK cohort of NMO patients [16].
5. Also low numbers of AQP4268–285-specific T cells can 
initiate large lesions with AQP4 loss. These findings 
recapitulate observations which have been made earlier 
in an EAE model using myelin basic protein-specific 
T cells with demyelinating anti-MOG antibodies [17], 
and suggest that the large, astrocyte-destructive lesions 
in NMO-IgG seropositive NMO patients could be pro-
voked by the action of very few AQP4-specific T cells.
 In Lewis rats, AQP4268–285 is highly encephalitogenic. 
For the time being, we do not know yet whether intra-
cellular AQP4 fragments also contain highly encepha-
litogenic antigens in humans, since their MHC could 
select different epitopes. Does this mean that AQP4-
specific T cells recognizing weakly encephalitogenic 
AQP4 epitopes are irrelevant for NMO in Lewis rats or 
NMO patients? Probably not. While certain antigenic 
fragments might not be present in sufficient amounts 
to warrant T cell infiltration into the intact CNS, i.e. 
to trigger the very first NMO lesion, they might play a 
crucial role in the propagation of relapses, for example 
when antigens are released from necrotic, astrocyte-
destructive lesions. Then, the liberated antigens might 
become available for local antigen presenting cells [13, 
26], and provide the basis for the activation of naive T 
cells within the CNS in a process called epitope spread-
ing [17]. At least in EAE and MS, this process under-
lies the shift of autoreactivity from primary initiating 
self-determinants, which invariably regress with time 
and might even become undetectable during periods of 
disease progression, to sustained secondary autoreac-
tivity [37]. Considering the fact that AQP4 contains a 
large number of potential T cell epitopes, not only in 
mice and rats [12, 25, 32], but also in humans [6, 23] 
(Fig. 1), it is tempting to speculate that this might be a 
strong argument in favor of very early T cell vaccina-
tion, and a strong counter-argument for later T cell vac-
cination as a therapeutic option for NMO patients.
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